Glaukos Corp
GKOS
Detailliertes Diagramm anzeigen
88.350USD
+4.490+5.35%
Handelsschluss 11/10, 16:00（ET）Kurse um 15 Minuten verzögert
5.07BMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+5.35%
5 Tage
+1.10%
1 Monat
+7.01%
6 Monate
-1.79%
Seit Jahresbeginn
-41.08%
1 Jahr
-37.67%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Glaukos Corp
Währung: USD Aktualisiert: 2025-11-10Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer durchschnittlichen Aktienmarktperformance zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Glaukos Corp Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
16
Analysten
Kaufen
Aktuelles Rating
120.500
Kursziel
+43.69%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Glaukos Corp Highlights
HöhepunkteRisiko
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=35.57%)
high_profit_growth
high_profit_growth_desc%!(EXTRA string=383.48M)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=-57.23)
institutional_increasing_position
institutional_increasing_position_desc%!(EXTRA string=61.34M, string=0.38%)
institutional_hold%!(EXTRA string=HACAX)
institutional_hold_desc%!(EXTRA string=HACAX, string=11.62K)
Glaukos Corp Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Glaukos Corp Informationen
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
BörsenkürzelGKOS
UnternehmenGlaukos Corp
CEOMr. Thomas William Burns
Websitehttps://www.glaukos.com
Verwandte Finanzinstrumente
-0.81%
-0.37%
+0.69%
+2.89%
+0.89%
+0.59%
-0.28%
+0.50%
-3.63%
-1.84%
+1.10%
-2.43%
-4.41%
+0.16%
+2.14%
+0.83%
+0.30%
-0.26%
+0.57%
-0.55%Beliebte Symbole
